Transcatheter tricuspid valve replacement for functional tricuspid regurgitation after left‐sided valve surgery: A single‐center experience

Background Functional tricuspid regurgitation (FTR) following left‐sided valve surgery (LSVS) is of clinical significance due to its high recurrence and mortality rates. Transcatheter therapy presents a potential solution to address this issue. Aims The study aimed to assess the safety and efficacy of transcatheter tricuspid valve replacement using the Lux‐Valve system in a single center for patients with FTR after LSVS. Methods From June 2020 to April 2023, 20 patients with symptomatic severe FTR after LSVS were referred to our center. A multidisciplinary cardiac team evaluated these patients for suitability for transcatheter tricuspid valve replacement with Lux‐Valve systems. Primary efficacy and safety endpoints were immediate postoperative tricuspid regurgitation severity ≤ moderate and major adverse events during follow‐up. Results Twenty patients (average age 65.7 ± 7.4 years; 65.0% women) successfully underwent Lux‐Valve system implantation after LSVS. All patients achieved ≤ moderate tricuspid regurgitation immediately after the procedure. Only one patient (5.0%) experienced a procedure‐related major adverse event, leading to in‐hospital mortality due to pulmonary infection. At the 6‐month follow‐up, 17 patients (89.5%) improved to New York Heart Association functional class I to II (p